These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27893709)

  • 1. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.
    Yu L; Liang Y; Cao X; Wang X; Gao H; Lin SY; Schiff R; Wang XS; Li K
    Oncogene; 2017 May; 36(20):2910-2918. PubMed ID: 27893709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 3. G9a-mediated methylation of ERα links the PHF20/MOF histone acetyltransferase complex to hormonal gene expression.
    Zhang X; Peng D; Xi Y; Yuan C; Sagum CA; Klein BJ; Tanaka K; Wen H; Kutateladze TG; Li W; Bedford MT; Shi X
    Nat Commun; 2016 Mar; 7():10810. PubMed ID: 26960573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SnoN oncoprotein enhances estrogen receptor-α transcriptional activity.
    Band AM; Laiho M
    Cell Signal; 2012 Apr; 24(4):922-30. PubMed ID: 22227247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells.
    Kala R; Tollefsbol TO
    PLoS One; 2016; 11(5):e0155057. PubMed ID: 27159275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PELP1 oncogenic functions involve CARM1 regulation.
    Mann M; Cortez V; Vadlamudi R
    Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
    Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
    Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone acetyltransferase Hbo1 destabilizes estrogen receptor α by ubiquitination and modulates proliferation of breast cancers.
    Iizuka M; Susa T; Takahashi Y; Tamamori-Adachi M; Kajitani T; Okinaga H; Fukusato T; Okazaki T
    Cancer Sci; 2013 Dec; 104(12):1647-55. PubMed ID: 24125069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
    Nassa G; Salvati A; Tarallo R; Gigantino V; Alexandrova E; Memoli D; Sellitto A; Rizzo F; Malanga D; Mirante T; Morelli E; Nees M; Åkerfelt M; Kangaspeska S; Nyman TA; Milanesi L; Giurato G; Weisz A
    Sci Adv; 2019 Feb; 5(2):eaav5590. PubMed ID: 30775443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers.
    Salvati A; Giurato G; Lamberti J; Terenzi I; Crescenzo L; Melone V; Palo L; Giordano A; Sabbatino F; Roscigno G; Quintavalle C; Condorelli G; Rizzo F; Tarallo R; Nassa G; Weisz A
    Mol Cancer; 2024 Aug; 23(1):160. PubMed ID: 39113071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.
    Liu W; Ip MM; Podgorsak MB; Das GM
    Breast Cancer Res Treat; 2009 May; 115(1):43-50. PubMed ID: 18481172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic ubiquitin E3 ligase activity of histone acetyltransferase Hbo1 for estrogen receptor α.
    Iizuka M; Susa T; Tamamori-Adachi M; Okinaga H; Okazaki T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(7):498-510. PubMed ID: 28769019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells.
    Zhao C; Matthews J; Tujague M; Wan J; Ström A; Toresson G; Lam EW; Cheng G; Gustafsson JA; Dahlman-Wright K
    Cancer Res; 2007 Apr; 67(8):3955-62. PubMed ID: 17440111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
    Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
    Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
    Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L
    Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha.
    Han L; Liu B; Jiang L; Liu J; Han S
    Tumour Biol; 2016 Oct; 37(10):13205-13214. PubMed ID: 27456360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.